---
title: "Catalyst Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Catalyst Pharmaceuticals, Inc. - CPRX"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285824076.md"
description: "Kahn Swick & Foti, LLC is investigating the proposed sale of Catalyst Pharmaceuticals, Inc. (CPRX) to Angelini Pharma S.p.A., where shareholders would receive $31.50 per share. The firm aims to assess whether this price and the sale process are adequate or if they undervalue the company. Shareholders who believe the transaction undervalues Catalyst can contact KSF for more information."
datetime: "2026-05-10T00:34:13.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285824076.md)
  - [en](https://longbridge.com/en/news/285824076.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285824076.md)
---

# Catalyst Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Catalyst Pharmaceuticals, Inc. - CPRX

Catalyst Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Catalyst Pharmaceuticals, Inc. - CPRX

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Catalyst Pharmaceuticals, Inc. (NasdaqCM: CPRX) to Angelini Pharma S.p.A. Under the terms of the proposed transaction, shareholders of Catalyst will receive $31.50 in cash for each share of Catalyst that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.

If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn (lewis.kahn@ksfcounsel.com) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nasdaqcm-cprx/ to learn more.

To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com.

CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn

Kahn Swick & Foti, LLC  
Lewis Kahn, Managing Partner  
lewis.kahn@ksfcounsel.com  
855-768-1857  
1100 Poydras St., Suite 960  
New Orleans, LA 70163

View source version on businesswire.com: https://www.businesswire.com/news/home/20260509833692/en/

### Related Stocks

- [CPRX.US](https://longbridge.com/en/quote/CPRX.US.md)

## Related News & Research

- [Angelini Buyout And Firdapse Settlement Reframe Catalyst Pharmaceuticals Story](https://longbridge.com/en/news/286669201.md)
- [Are KALV, GBTG, MDV, CPRX Obtaining Fair Deals for their Shareholders?](https://longbridge.com/en/news/286973039.md)
- [Assertio Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Assertio Holdings, Inc. - ASRT](https://longbridge.com/en/news/286953224.md)
- [Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Hetero Labs Ltd. | CPRX Stock News](https://longbridge.com/en/news/285497648.md)
- [DPL LLC Announces Expiration of Previously Announced Consent Solicitation | AES Stock News](https://longbridge.com/en/news/286416856.md)